Clinical Trials | November 29, 2023
Roche expands hepatitis diagnostics portfolio
Almost 300 million people globally have chronic hepatitis B
Almost 300 million people globally have chronic hepatitis B
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
